Rabies vaccine

SCOPE — READ FIRST. This page is a vaccine-group page whose brand list names TWO products, Rabipur and Verorab. The bundle contains a UK SPC for RABIPUR only (eMC product 100651); there is no eMC entry and no openFDA entry for Verorab. Every figure above is therefore Rabipur's, and the dose text says so. A per-dose volume and the reconstituted presentation are product-specific properties of a rabies vaccine, not class properties, so 1.0 mL must not be assumed to govern any other manufacturer's product — a clinician using a different rabies vaccine must read that product's own SPC. Regimen eligibility is likewise set per product and by national policy: §4.2 itself defers to official recommendations ('Rabipur should be used in accordance with official recommendations'; 'Serological testing ... should be conducted in accordance with official recommendations'), and post-exposure regimen choice in the UK is governed by the current national rabies post-exposure prophylaxis policy according to exposure category and the patient's immunisation and immune status. EXPOSURE CATEGORIES (§4.2, Table 2): category I (touching or feeding animals, licks on intact skin, contact of intact skin with secretions) — none required if a reliable case history is available; category II (nibbling of uncovered skin, minor scratches or abrasions without bleeding) — administer vaccine immediately; category III (single or multiple transdermal bites or scratches, licks on broken skin, contamination of mucous membrane with saliva, exposure to bats) — administer rabies vaccine immediately AND rabies immunoglobulin, preferably as soon as possible after initiation of PEP, and immunoglobulin can be injected up to 7 days after the first vaccine dose. Treatment may be stopped if the animal remains healthy throughout a 10-day observation period (dogs and cats only) or is proven negative by a reliable laboratory. Exposure to rodents, rabbits or hares does not routinely require rabies PEP. Bites to the head, neck, face, hands and genitals are category III because of the rich innervation of these areas. NO MAXIMUM DOSE IS PUBLISHED because §4.2 prints none — a rabies vaccine dose is a fixed per-dose volume given to a schedule, and no ceiling figure appears anywhere in the posology; none has been derived. IMMUNOSUPPRESSION (§4.2): immunosuppressive agents should not be administered during post-exposure therapy unless essential for the treatment of other conditions. §4.8 is truncated at the source-fetch limit (after the adverse-reaction table, within the reporting-of-suspected-reactions text), so the side-effect array below is near-complete but should be confirmed against the full SPC.

NOT A WEIGHT-BASED DOSE — dosePerKg is deliberately null. §4.2 states: 'Paediatric individuals should receive the same dose as adults (1.0 ml).' A rabies vaccine dose is a fixed per-dose volume, not a mg/kg figure, and no per-kilogram value exists in the label or has been derived. SITE: 'For adults and children ≥ 2 years of age, the vaccine should be administered into the deltoid muscle. For children < 2 years, the anterolateral area of the thigh is recommended.' In the two-site day-0 schedules, small children should receive one dose into the anterolateral region of each thigh. §4.1 licenses Rabipur for 'individuals of all ages', so no paediatric age floor is stated. §4.8: 'Frequency, type and severity of adverse reactions in children are expected to be the same as in adults.' Scope: Rabipur only, as for the adult dose.